Evexta Bio
Develops oncology drug candidates for patients with breast cancer, hematological cancers and solid tumors
Highlights
- New on EvolcAdded 2026-11-15
About Evexta Bio
Evexta Bio is a biopharmaceutical company developing two oncology drug candidates. Rupitasertib is an oral inhibitor of the S6K and AKT1/AKT3 pathways; EVX020 is an antibody-drug conjugate program using a KIF20A inhibitor as its payload.
The programs target breast cancer, hematological cancers and solid tumors. The company was founded by Truffle Capital and has alliances with CNRS, the Paoli-Calmettes Institute and Merck KGaA.
Product: Develops rupitasertib, an oral pathway inhibitor, and EVX020, an antibody-drug conjugate program for oncology.
Jobs at Evexta Bio
More biotech & pharma companies
Evolutive Agronomy
Biocontrol products for growers seeking to protect crops from root-knot nematodesYoung companyNew on EvolcExadex-Innov
Ex vivo human tissue models and research data for pharmaceutical, dermo-cosmetic and aesthetic medicine developersYoung companyNew on EvolcExpanscience
Develops skincare, rheumatology medicines and natural cosmetic ingredients for consumers and industryExtrasynthese
Phytochemical reference standards and custom natural-products chemistry services for research and quality-control laboratoriesNew on EvolcExystat
Clinical biometrics services for biotech, medtech and pharma sponsors running clinical studies, based in Malakoff, FranceNew on EvolcFabentech
Develops antibody-based emergency treatments for governments and health organizations facing biological threats
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Backend
- PHPHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-powered-by
- Response headerx-powered-by
- Response headerx-powered-by
Content management
- DrupalHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- LiteSpeedHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.